News Feed
Pieris Pharmaceuticals Presents Positive Preclinical Data on Lead Bispecific Immuno-Oncology Program
Tumor-targeting CD137/HER2 Bispecifics Exhibit Desired Drug-Like Properties and Tumor-Dependent T Cell Activation […]
Tumor-targeting CD137/HER2 Bispecifics Exhibit Desired Drug-Like Properties and Tumor-Dependent T Cell Activation […]
Interview with CEO Derek Elder […]
Interview with CEO Mark LeDoux […]
Interview with CEO Denis Corin […]
Interview with Charles Allen, CEO […]
Interview update with President Scott Jenkins […]
Interview with CEO Mike Durney […]
Interview with CEO Mary Puma […]
Wall Street Analyzer’s CEO Interview Series […]
Interview with CEO Dr. James Bailey […]
Copyright © 2019 The Wall Street Analyst, LLC. All rights reserved. Website by MyWebsiteSpot.com